Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond

Cancer

Volumn 117, Issue 6, 2011, Pages 1245-1252

  Lima, Lisa ^a   Bernal Mizrachi, Leon ^a   Saxe, Debra ^a   Mann, Karen P ^a   Tighiouart, Mourad ^a   Arellano, Martha ^a   Heffner, Leonard ^a   McLemore, Morgan ^a   Langston, Amelia ^a   Winton, Elliott ^a   Khoury, Hanna Jean ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

blood; chronic myeloid leukemia (CML); fluorescence in situ hybridization (FISH); monitoring; polymerase chain reaction (PCR)

Indexed keywords

BCR ABL1 PROTEIN; BOSUTINIB; CELL PROTEIN; DASATINIB; HOMOHARRINGTONINE; IMATINIB; NILOTINIB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BONE MARROW BIOPSY; CANCER STAGING; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; HUMAN TISSUE; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CYTOGENETIC ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC TESTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM STAGING; PIPERAZINES; POLYMERASE CHAIN REACTION; PROGNOSIS; PYRIMIDINES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79952375521     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25678     Document Type: Article

References (32)

1. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 2408-2417. (Pubitemid 44903745)
2. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 994-1004. (Pubitemid 36302244)
3. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007; 109: 5143-5150. (Pubitemid 46890528)
4. Quintas-Cardama A, Cortes JE, O'Brien S, et al. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer. 2009; 115: 2912-2921.
5. Kantarjian H, O'Brien S, Shan J, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008; 112: 837-845.
6. Le Gouill S, Talmant P, Milpied N, et al. Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. J Clin Oncol. 2000; 18: 1533-1538. (Pubitemid 30205400)
7. Kantarjian HM, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 2003; 9: 160-166. (Pubitemid 36109728)
8. Lesser ML, Dewald GW, Sison CP, et al. Correlation of 3 methods of measuring cytogenetic response in chronic myelocytic leukemia. Cancer Genet Cytogenet. 2002; 137: 79-84. (Pubitemid 35266851)
9. Hochhaus A, Lin F, Reiter A, et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood. 1996; 87: 1549-1555. (Pubitemid 26056920)
10. Wang L, Pearson K, Pillitteri L, et al. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol. 2002; 118: 771-777. (Pubitemid 35007381)
11. Lundan T, Juvonen V, Mueller MC, et al. Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia. Haematologica. 2008; 93: 178-185. (Pubitemid 351397705)
12. Landstrom AP, Ketterling RP, Knudson RA, et al. Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia. Leuk Lymphoma. 2006; 47: 2055-2061. (Pubitemid 44650080)
13. Jaffe ES, Harris NL, Stein H, Vardiman JW,. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
14. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology. Version 1. Fort Washington, PA: National Comprehensive Cancer Network; 2009. Available at:. Accessed in 2009.
15. Shaffer L,. An International System for Human Cytogenetic Nomenclature. In:, Tommerup N, ed. Basal, Switzerland: S. Karger; 2005.
16. Pinilla-Ibarz J, Quintas-Cardama A,. New agents in the treatment of chronic myelogenous leukemia. J Natl Compr Canc Netw. 2009; 7: 1028-1037.
17. Melo JV, Chuah C,. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. Hematology Am Soc Hematol Educ Program. 2008: 427-435.
18. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007; 109: 2303-2309. (Pubitemid 46425867)
19. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008; 111: 1834-1839. (Pubitemid 351451490)
20. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006; 108: 1809-1820. (Pubitemid 44394987)
21. Kantarjian HM, Smith TL, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med. 1995; 122: 254-261.
22. Jamieson CH,. Chronic myeloid leukemia stem cells. Hematology Am Soc Hematol Educ Program. 2008: 436-442.
23. Press RD, Willis SG, Laudadio J, et al. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood. 2009; 114: 2598-2605.
24. Buno I, Wyatt WA, Zinsmeister AR, et al. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood. 1998; 92: 2315-2321. (Pubitemid 28452972)
25. Testoni N, Marzocchi G, Luatti S, et al. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood. 2009; 114: 4939-4943.
26. Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer. 2003; 98: 1905-1911. (Pubitemid 37310233)
27. Terre C, Eclache V, Rousselot P, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia. 2004; 18: 1340-1346. (Pubitemid 39136741)
28. Feldman E, Najfeld V, Schuster M, et al. The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol. 2003; 31: 702-707. (Pubitemid 36945383)
29. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27: 6041-6051.
30. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003; 101: 3794-3800. (Pubitemid 36857848)
31. Deininger MW,. Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Hematol Educ Program. 2008: 419-26.
32. Baccarani M, Pane F, Saglio G,. Monitoring treatment of chronic myeloid leukemia. Haematologica. 2008; 93: 161-169.